Novartis receives EC Approval for next-gen anti-VEGF treatment for wet AMD21 Feb 2020
Beovu is the only anti-VEGF treatment approved in Europe for wet AMD that offers the option to start eligible patients on 3-month dosing intervals immediately after the loading phase.
Novartis has announced the European Commission (EC) has approved Beovu (brolucizumab) injection for the treatment of wet age-related macular degeneration (AMD). Beovu is the first EC-approved anti-VEGF treatment to demonstrate superior resolution of retinal fluid (IRF/SRF), a key marker of disease activity, versus aflibercept (secondary endpoints).
Beovu also offers the ability to start eligible wet AMD patients on a 3-month dosing interval immediately after the loading phase. The EC decision is applicable to all 27 European Union member states as well as the UK, Iceland, Norway and Liechtenstein.
“Currently, wet AMD patients, who are often older, can face significant challenges in managing their disease. We believe that Beovu, and its ability to resolve fluid, brings great therapeutic value that will help physicians optimize treatments for patients based on disease activity,” said Marie-France Tschudin, President Novartis Pharmaceuticals. “With the approval of this innovative biologic, Novartis is continuing to reimagine medicine for people living with wet AMD.”
“Drying the retina is one of the main goals in the treatment of wet AMD with anti-VEGF therapy,” said Frank Holz, Professor and Chairman, Department of Ophthalmology, University of Bonn, Germany. “Beovu, with its superior fluid resolution as demonstrated in the HAWK and HARRIER trials, will provide physicians with a new option to treat wet AMD.”
The EC approval was based on findings from the Phase III HAWK and HARRIER clinical trials, in which Beovu met the primary endpoint, demonstrating gains in best corrected visual acuity (BCVA) that were non-inferior to aflibercept at year one (week 48). Vision gains at year one were maintained at year two.
In fluid-related secondary endpoints, Beovu outperformed aflibercept. Significantly, fewer patients had intra-retinal and/or sub-retinal fluid (IRF/SRF), two fluids, which may disrupt the normal retinal structure and cause damage to the macula. In addition, Beovu showed superior reductions in central subfield thickness, another indicator of retinal fluid, at week 16 and at year one. Differences seen at year one were maintained at year two. In both trials, 30% fewer patients had signs of disease activity with Beovu versus aflibercept as early as week 16.
In HAWK and HARRIER, over half of patients were maintained on the 3-month dosing interval at year one. The remaining patients in the study were treated on a 2-month dosing interval.
“Today’s approval is a step forward for patients in Europe who have been looking for a new treatment option which may help them maintain their sight — and their independence — for longer,” said Christina Fasser, President, Retina International. “This can really help to alleviate a burden, not only on the patient themselves, but also on those who care for them."
In October 2019, Novartis received approval from the FDA for Beovu for the treatment of wet AMD. Beovu received Swissmedic approval in Switzerland and Australian TGA approval in January 2020, both for the treatment of wet AMD. Additional regulatory filings are currently underway in Canada, Japan and Brazil.
New blood test able to detect 50 cancer types
31 Mar 2020
Study data support blood test's ability to detect 50 types of cancer and identify where in the body the cancer is located.Read more
European patent granted for amatoxin conjugates for tumor therapy
31 Mar 2020
The patent covers the crosslinking of certain carrier molecules, for example, antibodies, via specific binding sites to amatoxins.Read more
ProBioGen selected for development and large-scale manufacturing services
24 Mar 2020
The Contract Development and Manufacturing Organization (CDMO) and technology provider will use its CHO.RiGHT expression platform for high-titer cell line development.Read more
Positive update on the development of new XF‐platform drug formulations
24 Mar 2020
Collaboration with MedPharm delivers data profiling new XF‐platform drug formulations as potential treatments for dermal and ocular infections.Read more
Alvotech and DKSH partner to bring key biosimilar to Asia
24 Mar 2020
Together, the companies will provide APAC markets with a cost-effective alternative to the largest-selling blockbuster medicine worldwide.Read more
Codexis and Takeda collaborate to advance novel gene therapies
23 Mar 2020
Partnership to leverage Codexis’ protein engineering platform for the discovery and development of novel transgenes for lysosomal storage disorders and blood factor deficiencies.Read more
Vaxxas HD-MAP to deliver vaccines directly to the skin
17 Mar 2020
Company awarded US$5 million grant for clinical study of measles and rubella vaccination using Vaxxas’ high-density, micro-array patch.Read more
Regeneron and Sanofi begin global Kevzara clinical trial program in patients with severe COVID-19
16 Mar 2020
The trial is the first controlled trial in the US to evaluate the effect of IL-6 inhibition prospectively in COVID-19 patients.Read more
Technique improves drug delivery system characterization
16 Mar 2020
Postnova Analytics' CF2000 Centrifugal Field Flow Fractionation (CF3) system is delivering exciting new data to scientists developing drug delivery systems.Read more
Nanoform and Orion collaborate on 'nanoformed' APIs
9 Mar 2020
Active pharmaceutical ingredients (APIs) nanoformed using the CESS process demonstrate promise for overcoming solubility and bioavailability challenges.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation